Expected Results

• Fundraising

• Business engage

• Strategic collaboration

Specific Organizations/VCs to Engage

• New Enterprise Associates (NEA), Kleiner Perkins, SV Health Investors, Advanced Technology Ventures

Short description

JelloX Biotech was established in 2018 as a next-generation pathology company that incorporates advanced NTHU licensed 3D pathology and AI technologies into medical applications. The company possesses multiple unique patented technologies that can obtain three-dimensional pathology images, increasing the dimensionality and amount of information, and combining with artificial intelligence solutions to deduce more accurate characteristic parameters to address the pain points of insufficient traditional pathological information. The company further integrates and launches a federated learning AI platform, which assists the medical end in connecting multiple institutions and types of diagnosing information, helping to improve the accurate diagnosis of cancer and clinical decision-making, thereby enhancing precise cancer treatment and patient well-being.

Core Technology

Advanced digital pathology technologies (3D pathology, Pathology AI)